Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALLA
2018-002872-42Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Durvalumab + standard concurrent chemoradiotherapy with Placebo + standard concurrent chemoradiotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jan 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-002872-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002872-42.